EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema

Shalini Virani, Akshay Bhatiwal, Parveen Rewri

Indian Journal of Pharmacology · 2024

DOI: 10.4103/ijp.ijp_58_24 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Pharmacology, 2024. Verfasst von Shalini Virani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Maharaja Agrasen Medical College, Agroha, Hisar, Haryana, India. Hauptthemen laut MEDLINE: Bevacizumab, Macular Edema, Biosimilar Pharmaceuticals, Cost-Benefit Analysis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Anti-vascular endothelial growth factor (VEGF) therapy restores retinal architecture and enhances vision in diabetic macular edema (DME). Bevacizumab is an off-label anti-VEGF drug that effectively treats DME. The safety and efficacy of bevacizumab biosimilars, which are more affordable than the original medication, still need to be established. This study aimed to assess the cost-effectiveness, efficacy, and safety of biosimilars for treating patients with naïve DME across various price ranges that are accessible in the Indian market. MATERIALS AND METHODS: Two biosimilars, BevaciRelTM (Reliance Life Sciences Pvt. Ltd.) and ZyBev (Cadila Healthcare Limited), were compared to their original, Avastin (Roche Products [India] Pvt. Ltd.), in a randomized, control study. Three end-notes were used to assess safety and efficacy: persistence, improvement, and adverse events. Cost-effective analysis was carried out using a decision-tree analysis model. RESULTS: This study included 69 (59%) men and 54 (41%) women with naïve DME. The cohort had an average log MAR visual acuity of 0.87 ± 0.22, and the central retinal thickness at baseline on OCT was 398.5 ± 37.61 μm. The visual acuity showed a similar improvement, and there was a decrease in central retinal thickness as observed on OCT across the groups. The incremental cost-effectiveness ratio was 10.8. CONCLUSIONS: The biosimilars of bevacizumab are safe and efficacious in treating DME in a cost-effective manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabMacular EdemaBiosimilar PharmaceuticalsCost-Benefit AnalysisDiabetic RetinopathyAngiogenesis InhibitorsHumansMaleFemaleMiddle AgedTreatment OutcomeAgedVisual AcuityIndiaAdult

Substanzen

BevacizumabBiosimilar PharmaceuticalsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, Maharaja Agrasen Medical College, Agroha, Hisar, Haryana, India.
  • Department of Ophthalmology, Maharaja Agrasen Medical College, Agroha, Hisar, Haryana, India.

Zitieren

APA

Virani, S., Bhatiwal, A., & Rewri, P. (2024). Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_58_24

Vancouver

Virani S, Bhatiwal A, Rewri P. Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema. Indian Journal of Pharmacology. 2024. doi:10.4103/ijp.ijp_58_24

BibTeX
@article{Virani2024,
  author = {Virani, Shalini and Bhatiwal, Akshay and Rewri, Parveen},
  title = {Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema},
  journal = {Indian Journal of Pharmacology},
  year = {2024},
  doi = {10.4103/ijp.ijp_58_24}
}
Kostenlos starten →